• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

埃塞俄比亚乳腺癌患者的血液免疫图谱揭示了不同形式的免疫逃逸。

Blood immune profiling of Ethiopian patients with breast cancer highlights different forms of immune escape.

作者信息

Yohannes Meron, Massa Chiara, Desalegn Zelalem, Stückrath Kathrin, Mueller Anja, Anberber Endale, Bekuretsion Yonas, Assefa Mathewos, Santos Pablo, Addissie Adamu, Bauer Marcus, Wickenhauser Claudia, Taylor Lesley, Vetter Martina, Kantelhardt Eva Johanna, Abebe Tamrat, Seliger Barbara

机构信息

Department of Microbiology, Immunology & Parasitology, School of Medicine, Addis Ababa University, Addis Ababa, Ethiopia.

Department of Medical Laboratory Science, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.

出版信息

Oncoimmunology. 2024 Dec 31;13(1):2436227. doi: 10.1080/2162402X.2024.2436227. Epub 2024 Dec 2.

DOI:10.1080/2162402X.2024.2436227
PMID:39621040
原文链接:
https://pmc.ncbi.nlm.nih.gov/articles/PMC11622621/
Abstract

Breast cancer (BC) is a leading cause of death worldwide, particularly also among African woman. In order to better stratify patients for the most effective (immuno-) therapy, an in depth characterization of the immune status of BC patients is required. In this study, a cohort of 65 Ethiopian patients with primary BC underwent immune profiling by multicolor flow cytometry on peripheral blood samples collected prior to surgery and to any other therapy. Comparison with peripheral blood samples from healthy donors highlighted a general activation of the immune system, accompanied by the presence of exhausted CD4 T cells and senescent CD8 T cells with an inverted CD4/CD8 ratio in approximately 50% of BC cases. Enhanced frequencies of γδ T cells, myeloid-derived suppressor cells and regulatory T cells were also found. Correlation with clinical parameters demonstrated a progressive reduction in T cell frequencies with increasing histopathological grading of the tumor. Differences in CD8 T cells and B cells were also noted among luminal and non-luminal BC subtypes. In conclusion, Ethiopian BC patients showed several alterations in the composition and activation status of the blood immune cell repertoire, which were phenotypically associated with immune suppression. The role of these immunological changes in the clinical outcome of patients with BC will have to be determined in follow-up studies and confirmed in additional patients' cohorts.

摘要

乳腺癌(BC)是全球主要的死亡原因之一,在非洲女性中尤为突出。为了更好地对患者进行分层以实施最有效的(免疫)治疗,需要深入了解BC患者的免疫状态。在本研究中,65名埃塞俄比亚原发性BC患者组成的队列在手术及任何其他治疗前采集的外周血样本上通过多色流式细胞术进行了免疫分析。与健康供体的外周血样本比较显示,免疫系统普遍激活,约50%的BC病例中存在耗竭的CD4 T细胞和衰老的CD8 T细胞,且CD4/CD8比值倒置。还发现γδ T细胞、髓系来源的抑制细胞和调节性T细胞的频率增加。与临床参数的相关性表明,随着肿瘤组织病理学分级的增加,T细胞频率逐渐降低。在管腔型和非管腔型BC亚型之间也注意到CD8 T细胞和B细胞的差异。总之,埃塞俄比亚BC患者的血液免疫细胞库组成和激活状态存在多种改变,这些改变在表型上与免疫抑制相关。这些免疫变化在BC患者临床结局中的作用必须在后续研究中确定,并在更多患者队列中得到证实。

相似文献

1
Blood immune profiling of Ethiopian patients with breast cancer highlights different forms of immune escape.埃塞俄比亚乳腺癌患者的血液免疫图谱揭示了不同形式的免疫逃逸。
Oncoimmunology. 2024 Dec 31;13(1):2436227. doi: 10.1080/2162402X.2024.2436227. Epub 2024 Dec 2.
2
Comparative analysis of CD4+ and CD8+ T cells in tumor tissues, lymph nodes and the peripheral blood from patients with breast cancer.乳腺癌患者肿瘤组织、淋巴结及外周血中CD4+和CD8+ T细胞的比较分析
Iran Biomed J. 2015;19(1):35-44. doi: 10.6091/ibj.1289.2014.
3
Frequency of CD4+ regulatory T cells, CD8+ T cells, and human papilloma virus infection in Egyptian Women with breast cancer.埃及乳腺癌女性患者中 CD4+ 调节性 T 细胞、CD8+ T 细胞和人乳头瘤病毒感染的频率。
Int J Immunopathol Pharmacol. 2020 Jan-Dec;34:2058738420966822. doi: 10.1177/2058738420966822.
4
Polyfunctional KLRG-1CD57 Senescent CD4 T Cells Infiltrate Tumors and Are Expanded in Peripheral Blood From Breast Cancer Patients.多功能 KLRG-1CD57 衰老 CD4 T 细胞浸润肿瘤,并在外周血中从乳腺癌患者中扩增。
Front Immunol. 2021 Jul 27;12:713132. doi: 10.3389/fimmu.2021.713132. eCollection 2021.
5
Association between αβ and γδ T-cell subsets and clinicopathological characteristics in patients with breast cancer.乳腺癌患者中αβ和γδ T细胞亚群与临床病理特征之间的关联。
Oncol Lett. 2020 Dec;20(6):325. doi: 10.3892/ol.2020.12188. Epub 2020 Oct 5.
6
Higher proportion of CD8+ T cells in the blood in healthy adults from Ethiopia and Bangladesh compared with Sweden.与瑞典相比,埃塞俄比亚和孟加拉国健康成年人血液中CD8 + T细胞的比例更高。
Trans R Soc Trop Med Hyg. 1997 Sep-Oct;91(5):618-22. doi: 10.1016/s0035-9203(97)90051-1.
7
Exploratory analysis of immune checkpoint receptor expression by circulating T cells and tumor specimens in patients receiving neo-adjuvant chemotherapy for operable breast cancer.探讨分析接受新辅助化疗的可手术乳腺癌患者循环 T 细胞和肿瘤标本中免疫检查点受体的表达。
BMC Cancer. 2020 May 19;20(1):445. doi: 10.1186/s12885-020-06949-4.
8
Concomitant Expression of CD39, CD69, and CD103 Identifies Antitumor CD8 T Cells in Breast Cancer Implications for Adoptive Cell Therapy.CD39、CD69 和 CD103 的共表达鉴定了乳腺癌中的抗肿瘤 CD8 T 细胞,这对过继细胞治疗有影响。
Curr Pharm Biotechnol. 2024;25(13):1747-1757. doi: 10.2174/1389201025666230901094219.
9
Tumor-infiltrating regulatory T cells, CD8/Treg ratio, and cancer stem cells are correlated with lymph node metastasis in patients with early breast cancer.肿瘤浸润调节性 T 细胞、CD8/Treg 比值和癌症干细胞与早期乳腺癌患者的淋巴结转移相关。
Breast Cancer. 2020 Sep;27(5):837-849. doi: 10.1007/s12282-020-01079-y. Epub 2020 Mar 16.
10
Circulating myeloid-derived suppressor cells: An independent prognostic factor in patients with breast cancer.循环髓系来源的抑制细胞:乳腺癌患者的独立预后因素。
J Cell Physiol. 2019 Apr;234(4):3515-3525. doi: 10.1002/jcp.26896. Epub 2018 Oct 26.

本文引用的文献

1
The Value of Tumor Infiltrating Lymphocytes (TIL) for Predicting the Response to Neoadjuvant Chemotherapy (NAC) in Breast Cancer according to the Molecular Subtypes.根据分子亚型评估肿瘤浸润淋巴细胞(TIL)对预测乳腺癌新辅助化疗(NAC)疗效的价值
Biomedicines. 2023 Nov 13;11(11):3037. doi: 10.3390/biomedicines11113037.
2
The Great Immune Escape: Understanding the Divergent Immune Response in Breast Cancer Subtypes.免疫大逃脱:理解乳腺癌亚型中的不同免疫反应。
Cancer Discov. 2023 Jan 9;13(1):23-40. doi: 10.1158/2159-8290.CD-22-0475.
3
Intrinsic subtypes in Ethiopian breast cancer patient.
埃塞俄比亚乳腺癌患者的内在亚型。
Breast Cancer Res Treat. 2022 Dec;196(3):495-504. doi: 10.1007/s10549-022-06769-z. Epub 2022 Oct 25.
4
Peripheral Blood Mononuclear Cell Populations Correlate with Outcome in Patients with Metastatic Breast Cancer.外周血单个核细胞群体与转移性乳腺癌患者的预后相关。
Cells. 2022 May 13;11(10):1639. doi: 10.3390/cells11101639.
5
Predictive and Prognostic Role of Peripheral Blood T-Cell Subsets in Triple-Negative Breast Cancer.外周血T细胞亚群在三阴性乳腺癌中的预测和预后作用
Front Oncol. 2022 Feb 15;12:842705. doi: 10.3389/fonc.2022.842705. eCollection 2022.
6
Landscape of Myeloid-derived Suppressor Cell in Tumor Immunotherapy.肿瘤免疫治疗中髓源性抑制细胞的概况
Biomark Res. 2021 Oct 24;9(1):77. doi: 10.1186/s40364-021-00333-5.
7
Peripheral blood immune markers in breast cancer: Differences in regulatory T cell abundance are related to clinical parameters.乳腺癌外周血免疫标志物:调节性 T 细胞丰度的差异与临床参数相关。
Clin Immunol. 2021 Nov;232:108847. doi: 10.1016/j.clim.2021.108847. Epub 2021 Sep 27.
8
Circulating immune biomarkers in peripheral blood correlate with clinical outcomes in advanced breast cancer.外周血循环免疫生物标志物与晚期乳腺癌的临床结局相关。
Sci Rep. 2021 Jul 13;11(1):14426. doi: 10.1038/s41598-021-93838-w.
9
Clinical trial data and emerging immunotherapeutic strategies: hormone receptor-positive, HER2- negative breast cancer.临床试验数据与新兴免疫治疗策略:激素受体阳性、人表皮生长因子受体2阴性乳腺癌
Breast Cancer Res Treat. 2021 Aug;189(1):1-13. doi: 10.1007/s10549-021-06291-8. Epub 2021 Jul 2.
10
Immunosuppressive Mechanisms of Regulatory B Cells.调节性 B 细胞的免疫抑制机制。
Front Immunol. 2021 Apr 29;12:611795. doi: 10.3389/fimmu.2021.611795. eCollection 2021.